Radiotherapy sensitizer and preparation method thereof

Abstract

The invention belongs to the technical field of radiotherapy sensitizers, and particularly relates to a radiotherapy sensitizer and a preparation method thereof. The raw materials comprise the following components in parts by weight: 10 to 15 parts of hydroxide of alkali metal, 6 to 8 parts of bismuthate, 2 to 4 parts of a slow-release manganese composition, 4 to 6 parts of a surfactant, 2 to 6 parts of hyaluronic acid, 3 to 5 parts of an emulsifier, 1 to 5 parts of 5-azacytidine, 6 to 8 parts of mannitol, 3 to 6 parts of PLGA-PEI nano colloidal particles, 3 to 6 parts of amifostine, 5 to 8 parts of hypericin and 6 to 8 parts of HIF-1alpha-siRNA. The traditional Chinese medicine composition has the advantages that the immunity of a patient can be improved, the curative effect can be further improved, and the adverse reaction caused by radiotherapy can be reduced.

Description

Technical Field

[0001] The present invention relates to the technical field of radiotherapy sensitizers, in particular to a radiotherapy sensitizer and a preparation method thereof. Background Art

[0002] The incidence of malignant tumors has been increasing year by year worldwide, and the mortality rate has remained high, seriously threatening human survival and health. Radiotherapy, as a non-invasive tumor treatment method, is widely used in the treatment of different types of tumors. In tumor radiotherapy, after tumor cells absorb a certain amount of radiation energy, the rays can directly interact with intracellular biomacromolecules to produce free radicals, causing DNA molecules to break and cross-link; the rays can also cause the ionization of water molecules in the tissue to produce free radicals, which then react with biomacromolecules to cause cell damage and death, thereby achieving the effect of inhibiting tumor growth. However, existing radiotherapy sensitizers do not have the function of improving people's immunity and have limitations. Therefore, a radiotherapy sensitizer and a preparation method thereof are invented. Summary of the invention

[0003] In view of the above and / or existing problems in a radiotherapy sensitizer and a preparation method thereof, the present invention is proposed.

[0004] Therefore, the object of the present invention is to provide a radiotherapy sensitizer and a preparation method thereof, which can solve the above-mentioned existing problems.

[0005] To solve the above technical problems, according to one aspect of the present invention, the present invention provides the following technical solutions:

[0006] A radiotherapy sensitizer comprises raw materials, wherein the raw materials comprise, by weight, 10-15 parts of alkali metal hydroxide, 6-8 parts of bismuthate, 2-4 parts of sustained-release manganese composition, 4-6 parts of surfactant, 2-6 parts of hyaluronic acid, 3-5 parts of emulsifier, 1-5 parts of 5-azacytidine, 6-8 parts of mannitol, 3-6 parts of PLGA-PEI nano-particles, 3-6 parts of amifostine, 5-8 parts of hypericin, 6-8 parts of HIF-1α-siRNA, 4-10 parts of immune agent, 1-5 parts of glutathione and 2-4 parts of celecoxib.

[0007] As a preferred embodiment of the radiotherapy sensitizer described in the present invention, the ingredients in the raw materials include, by weight, 10 parts of alkali metal hydroxide, 6 parts of bismuthate, 2 parts of sustained-release manganese composition, 4 parts of surfactant, 2 parts of hyaluronic acid, 3 parts of emulsifier, 1 part of 5-azacytidine, 6 parts of mannitol, 3 parts of PLGA-PEI nanoparticles, 3 parts of amifostine, 5 parts of hypericin, 6 parts of HIF-1α-siRNA, 4 parts of immune agent, 1 part of glutathione, and 2 parts of celecoxib.

[0008] As a preferred embodiment of the radiotherapy sensitizer described in the present invention, the ingredients in the raw materials include, by weight, 12.5 parts of alkali metal hydroxide, 7 parts of bismuthate, 3 parts of sustained-release manganese composition, 5 parts of surfactant, 4 parts of hyaluronic acid, 4 parts of emulsifier, 3 parts of 5-azacytidine, 7 parts of mannitol, 4.5 parts of PLGA-PEI nanoparticles, 4.5 parts of amifostine, 6.5 parts of hypericin, 7 parts of HIF-1α-siRNA, 7 parts of immune agent, 3 parts of glutathione, and 3 parts of celecoxib.

[0009] As a preferred embodiment of the radiotherapy sensitizer described in the present invention, the ingredients in the raw materials include, by weight, 15 parts of alkali metal hydroxide, 8 parts of bismuthate, 4 parts of sustained-release manganese composition, 6 parts of surfactant, 6 parts of hyaluronic acid, 5 parts of emulsifier, 5 parts of 5-azacytidine, 8 parts of mannitol, 6 parts of PLGA-PEI nanoparticles, 6 parts of amifostine, 8 parts of hypericin, 8 parts of HIF-1α-siRNA, 10 parts of immune agent, 5 parts of glutathione, and 4 parts of celecoxib.

[0010] As a preferred embodiment of the radiosensitizer described in the present invention, the surfactant is polysorbate-20.

[0011] As a preferred embodiment of the radiosensitizer described in the present invention, the emulsifier is a mixture of one or more of polyvinyl pyrrolidone, poloxamer, low molecular weight polyethylene oxide, and polyethylene glycol.

[0012] As a preferred embodiment of the radiotherapy sensitizer described in the present invention, the raw materials of the immune agent include, by weight: 8-12 parts of water, 4-10 parts of kiwi fruit, 2-10 parts of honey, 4-6 parts of kohlrabi, 2-6 parts of garlic, 1-5 parts of Codonopsis pilosula, 2-6 parts of Astragalus, 3-5 parts of Salvia miltiorrhiza, 4-10 parts of Cordyceps sinensis, 1-3 parts of Ganoderma lucidum, 2-6 parts of Lycium barbarum, and 1-3 parts of Angelica sinensis.

[0013] As a preferred embodiment of the radiosensitizer of the present invention, the preparation process of the immunogenic agent is as follows:

[0014] Process 1: Use a juicer to squeeze kiwi fruit, kohlrabi, garlic, Codonopsis pilosula, Astragalus membranaceus, Salvia miltiorrhiza, Cordyceps sinensis, Ganoderma lucidum, wolfberry and angelica into juice, and then mix them;

[0015] Step 2: Mix water and honey;

[0016] Process 3: After the mixing is completed, the mixture in process 1 and the mixture in process 2 are mixed;

[0017] Process 4: Filter the mixture in process 3 to obtain the immune agent.

[0018] As a preferred embodiment of the radiotherapy sensitizer described in the present invention, the mixing temperature in process two is 100°C-110°C, and the mixing time is 1min-3min; the mixing temperature in process three is 110°C-120°C, and the mixing time is 8min-12min.

[0019] A method for preparing a radiotherapy sensitizer comprises the following specific steps:

[0020] Step 1: respectively mixing hypericin, PLGA-PEI nanoparticles, HIF-1α-siRNA, an emulsifier, hyaluronic acid, and an alkali metal hydroxide and bismuth salt to obtain a mixture A and a mixture B;

[0021] Step 2: Add the sustained-release manganese composition, surfactant, 5-azacytidine, mannitol, amifostine, immune agent, glutathione and celecoxib to the reactor in sequence for mixing, with the interval time of each component being 30s-35s to obtain mixture C, and then mix mixture A, mixture B and mixture C to obtain a radiotherapy sensitizer.

[0022] Compared with existing technologies:

[0023] By selecting alkali metal hydroxide, bismuthate, sustained-release manganese composition, surfactant, hyaluronic acid, emulsifier, -azacytidine, mannitol, PLGA-PEI nanoparticles, amifostine, hypericin, HIF-α-siRNA, immune agent, glutathione and celecoxib as raw materials of radiotherapy sensitizer, the immunity of patients can be improved, thereby not only improving the therapeutic effect but also reducing the adverse reactions caused by radiotherapy. DETAILED DESCRIPTION

[0024] In order to make the objectives, technical solutions and advantages of the present invention more clear, the embodiments of the present invention will be described in further detail below.

[0025] Embodiment 1:

[0026] The invention provides a radiotherapy sensitizer, comprising raw materials, which include, by weight, 10 parts of alkali metal hydroxide, 6 parts of bismuthate, 2 parts of sustained-release manganese composition, 4 parts of surfactant, 2 parts of hyaluronic acid, 3 parts of emulsifier, 1 part of 5-azacytidine, 6 parts of mannitol, 3 parts of PLGA-PEI nano-particles, 3 parts of amifostine, 5 parts of hypericin, 6 parts of HIF-1α-siRNA, 4 parts of immune agent, 1 part of glutathione and 2 parts of celecoxib;

[0027] in:

[0028] Bismuth salts have anti-acid, analgesic and antibacterial effects. Surfactants are compounds that can significantly reduce the surface tension or interfacial tension between two liquids, between a liquid and a gas, and between a liquid and a solid. Hyaluronic acid has moisturizing, anti-aging, anti-ultraviolet, wound healing, anti-bacterial and anti-inflammatory effects. 5-Azacytidine is a DNA methyltransferase inhibitor that can consume enzyme activity, induce demethylation and activation of silent genes, improve the efficiency of stem cell reprogramming, and induce mesenchymal stem cells to differentiate into cardiomyocytes. Mannitol is a good diuretic in medicine, which can reduce intracranial pressure, intraocular pressure, and treat kidney medicine, dehydration medicine, sugar substitute, and is also used as an excipient for tablets and a diluent for solids and liquids. PLGA-PEI nanoparticles are biodegradable polymers for drug encapsulation, drug solubilization and drugs, and can be used to prepare new targeted nanoparticles such as micelles or vesicles. Amifostine is a normal cell protector, which is mainly used in clinical adjuvant treatment of various cancers. Hypericin has the function of removing retroviruses both in vivo and in vitro, and has a strong antiviral effect, as well as the effects of inhibiting the central nervous system, calming and enhancing immunity. HIF-1α-siRNA is the key hub for destroying the tumor's adaptation to the hypoxic environment, thereby inhibiting tumor growth and enhancing radiotherapy sensitivity. Glutathione can help maintain normal immune system function and has antioxidant, integrated detoxification effects. Celecoxib is used to relieve the symptoms and signs of osteoarthritis, relieve the symptoms and signs of adult rheumatoid arthritis, and treat acute pain in adults.

[0029] The alkali metal hydroxide is a mixture of one or more of sodium hydroxide and potassium hydroxide.

[0030] The sustained-release manganese composition is divalent manganese loaded by a carrier, the carrier is a pharmaceutically acceptable carrier, and the carrier is a mixture of one or more of polysaccharides and proteins.

[0031] The polysaccharide is a mixture of one or more of cellulose, glycogen, and dextran, and the protein is a mixture of one or more of globulin, hemoglobin, myosin, and transferrin.

[0032] The surfactant is polysorbate 20.

[0033] The emulsifier is a mixture of one or more of polyvinyl pyrrolidone, poloxamer, low molecular weight polyoxyethylene and polyethylene glycol.

[0034] The raw materials of the immune agent include, by weight: 8 parts of water, 4 parts of kiwi fruit, 2 parts of honey, 4 parts of kohlrabi, 2 parts of garlic, 1 part of Codonopsis pilosula, 2 parts of Astragalus, 3 parts of Salvia miltiorrhiza, 4 parts of Cordyceps sinensis, 1 part of Ganoderma lucidum, 2 parts of Lycium barbarum, and 1 part of Angelica sinensis;

[0035] The preparation process of the immunizing agent is as follows:

[0036] Process 1: Use a juicer to squeeze kiwi fruit, kohlrabi, garlic, Codonopsis pilosula, Astragalus membranaceus, Salvia miltiorrhiza, Cordyceps sinensis, Ganoderma lucidum, wolfberry and angelica into juice, and then mix them;

[0037] Process 2: Mixing water and honey, wherein the mixing temperature is 100°C and the mixing time is 1 minute;

[0038] Process 3: After the mixing is completed, the mixture in process 1 and the mixture in process 2 are mixed, wherein the mixing temperature is 110° C. and the mixing time is 8 minutes;

[0039] Process 4: Filter the mixture in process 3 to obtain the immune agent.

[0040] A method for preparing a radiotherapy sensitizer comprises the following specific steps:

[0041] Step 1: Mix hypericin, PLGA-PEI nanoparticles and HIF-1α-siRNA, then add an emulsifier to allow the mutually immiscible hypericin, PLGA-PEI nanoparticles and HIF-1α-siRNA to form a stable emulsion, and then let it stand;

[0042] Step 2: adding hyaluronic acid to the emulsion to form a coating on the periphery of the emulsion, thereby obtaining a mixture A;

[0043] Step 3: Mixing and heating the alkali metal hydroxide and the bismuthate to dissolve the two, and then washing with deionized water to obtain a mixture B;

[0044] Step 4: adding the sustained-release manganese composition, surfactant, 5-azacytidine, mannitol, amifostine, immune agent, glutathione and celecoxib to the reaction kettle in sequence and mixing them, with the interval time of each component being 30 seconds, to obtain a mixture C;

[0045] Step 5: Mix mixture A, mixture B and mixture C to obtain a radiosensitizer.

[0046] Embodiment 2:

[0047] The invention provides a radiotherapy sensitizer, comprising raw materials, which include, by weight, 12.5 parts of alkali metal hydroxide, 7 parts of bismuthate, 3 parts of sustained-release manganese composition, 5 parts of surfactant, 4 parts of hyaluronic acid, 4 parts of emulsifier, 3 parts of 5-azacytidine, 7 parts of mannitol, 4.5 parts of PLGA-PEI nano-particles, 4.5 parts of amifostine, 6.5 parts of hypericin, 7 parts of HIF-1α-siRNA, 7 parts of immune agent, 3 parts of glutathione and 3 parts of celecoxib.

[0048] The alkali metal hydroxide is a mixture of one or more of sodium hydroxide and potassium hydroxide.

[0049] The sustained-release manganese composition is divalent manganese loaded by a carrier, the carrier is a pharmaceutically acceptable carrier, and the carrier is a mixture of one or more of polysaccharides and proteins.

[0050] The polysaccharide is a mixture of one or more of cellulose, glycogen, and dextran, and the protein is a mixture of one or more of globulin, hemoglobin, myosin, and transferrin.

[0051] The surfactant is polysorbate 20.

[0052] The emulsifier is a mixture of one or more of polyvinyl pyrrolidone, poloxamer, low molecular weight polyoxyethylene and polyethylene glycol.

[0053] The raw materials of the immune agent include, by weight: 10 parts of water, 7 parts of kiwi fruit, 6 parts of honey, 5 parts of kohlrabi, 4 parts of garlic, 3 parts of codonopsis, 4 parts of astragalus, 4 parts of salvia, 7 parts of cordyceps, 2 parts of ganoderma lucidum, 4 parts of wolfberry, and 2 parts of angelica;

[0054] The preparation process of the immunizing agent is as follows:

[0055] Process 1: Use a juicer to squeeze kiwi fruit, kohlrabi, garlic, Codonopsis pilosula, Astragalus membranaceus, Salvia miltiorrhiza, Cordyceps sinensis, Ganoderma lucidum, wolfberry and angelica into juice, and then mix them;

[0056] Step 2: Mix water and honey, wherein the mixing temperature is 105°C and the mixing time is 2 minutes;

[0057] Process 3: After the mixing is completed, the mixture in process 1 and the mixture in process 2 are mixed, wherein the mixing temperature is 115° C. and the mixing time is 10 min;

[0058] Process 4: Filter the mixture in process 3 to obtain the immune agent.

[0059] A method for preparing a radiotherapy sensitizer comprises the following specific steps:

[0060] Step 1: Mix hypericin, PLGA-PEI nanoparticles and HIF-1α-siRNA, then add an emulsifier to allow the mutually immiscible hypericin, PLGA-PEI nanoparticles and HIF-1α-siRNA to form a stable emulsion, and then let it stand;

[0061] Step 2: adding hyaluronic acid to the emulsion to form a coating on the periphery of the emulsion, thereby obtaining a mixture A;

[0062] Step 3: Mixing and heating the alkali metal hydroxide and the bismuthate to dissolve the two, and then washing with deionized water to obtain a mixture B;

[0063] Step 4: adding the sustained-release manganese composition, surfactant, 5-azacytidine, mannitol, amifostine, immune agent, glutathione and celecoxib to the reaction kettle in sequence for mixing, with the interval time of each component being 32.5 seconds, to obtain a mixture C;

[0064] Step 5: Mix mixture A, mixture B and mixture C to obtain a radiosensitizer.

[0065] Embodiment 3:

[0066] The invention provides a radiotherapy sensitizer, comprising raw materials. The raw materials include, by weight, 15 parts of alkali metal hydroxide, 8 parts of bismuthate, 4 parts of sustained-release manganese composition, 6 parts of surfactant, 6 parts of hyaluronic acid, 5 parts of emulsifier, 5 parts of 5-azacytidine, 8 parts of mannitol, 6 parts of PLGA-PEI nano-particles, 6 parts of amifostine, 8 parts of hypericin, 8 parts of HIF-1α-siRNA, 10 parts of immune agent, 5 parts of glutathione and 4 parts of celecoxib.

[0067] The alkali metal hydroxide is a mixture of one or more of sodium hydroxide and potassium hydroxide.

[0068] The sustained-release manganese composition is divalent manganese loaded by a carrier, the carrier is a pharmaceutically acceptable carrier, and the carrier is a mixture of one or more of polysaccharides and proteins.

[0069] The polysaccharide is a mixture of one or more of cellulose, glycogen, and dextran, and the protein is a mixture of one or more of globulin, hemoglobin, myosin, and transferrin.

[0070] The surfactant is polysorbate 20.

[0071] The emulsifier is a mixture of one or more of polyvinyl pyrrolidone, poloxamer, low molecular weight polyoxyethylene and polyethylene glycol.

[0072] The raw materials of the immune agent include, by weight: 12 parts of water, 10 parts of kiwi fruit, 10 parts of honey, 6 parts of kohlrabi, 6 parts of garlic, 5 parts of codonopsis, 6 parts of astragalus, 5 parts of salvia, 10 parts of cordyceps, 3 parts of ganoderma, 6 parts of wolfberry, and 3 parts of angelica;

[0073] The preparation process of the immunizing agent is as follows:

[0074] Process 1: Use a juicer to squeeze kiwi fruit, kohlrabi, garlic, Codonopsis pilosula, Astragalus membranaceus, Salvia miltiorrhiza, Cordyceps sinensis, Ganoderma lucidum, wolfberry and angelica into juice, and then mix them;

[0075] Step 2: Mix water and honey, wherein the mixing temperature is 110°C and the mixing time is 3 minutes;

[0076] Process 3: After the mixing is completed, the mixture in process 1 and the mixture in process 2 are mixed, wherein the mixing temperature is 120° C. and the mixing time is 12 minutes;

[0077] Process 4: Filter the mixture in process 3 to obtain the immune agent.

[0078] A method for preparing a radiotherapy sensitizer comprises the following specific steps:

[0079] Step 1: Mix hypericin, PLGA-PEI nanoparticles and HIF-1α-siRNA, then add an emulsifier to allow the mutually immiscible hypericin, PLGA-PEI nanoparticles and HIF-1α-siRNA to form a stable emulsion, and then let it stand;

[0080] Step 2: adding hyaluronic acid to the emulsion to form a coating on the periphery of the emulsion, thereby obtaining a mixture A;

[0081] Step 3: Mixing and heating the alkali metal hydroxide and the bismuthate to dissolve the two, and then washing with deionized water to obtain a mixture B;

[0082] Step 4: adding the sustained-release manganese composition, surfactant, 5-azacytidine, mannitol, amifostine, immune agent, glutathione and celecoxib to the reaction kettle in sequence and mixing them, with the interval time of each component being 35 seconds, to obtain a mixture C;

[0083] Step 5: Mix mixture A, mixture B and mixture C to obtain a radiosensitizer.

[0084] The radiosensitizers prepared in Examples 1-3 above were compared to obtain the following data:

[0085] Example 1 Example 2 Example 3 Immunity (mg / L) 0.21mg / L 0.27mg / L 0.24mg / L Efficacy good good good

[0086] As can be seen from the above table, the radiosensitizers prepared in Examples 1-3 have good performance in immunity and efficacy, but the different proportions of alkali metal hydroxide, bismuthate, sustained-release manganese composition, surfactant, hyaluronic acid, emulsifier, -azacytidine, mannitol, PLGA-PEI nanoparticles, amifostine, hypericin, HIF-α-siRNA, immune agent, glutathione, and celecoxib result in different effects of the radiosensitizers on immunity and efficacy. After use, Example 2 has the best effect.

[0087] test:

[0088] 0.1 mL of 1.5 × 10 6 A suspension of 5×10 B16F10 tumor cells / mL was injected subcutaneously into the right abdomen of the mouse. 5 A suspension of B16F10 tumor cells of 100 / mL was injected subcutaneously into the left abdomen of mice. The tumor on the right side grew to about 100 mm. 3 Inject radiosensitizer into the tumor at about 1:10 p.m.

[0089] Among them: 24 hours after intratumoral administration, the mice were killed by cervical dislocation, and the tumor tissues of the mice were taken and immersed in 1 mL of Trizol and handed over to Shanghai Lingen Biotechnology Co., Ltd. to complete the extraction of tumor tissue RNA and RNA-Seq experiments. The iDEP method developed by GeSX et al. was used to analyze and process the transcriptomics experimental data, and a cluster analysis diagram of relative gene expression was drawn;

[0090] The results showed that the expression of interferon genes and downstream related genes in the tumors of mice was significantly upregulated, which indicates that radiosensitizer combined with radiotherapy can reverse the tumor immunosuppressive microenvironment and promote the body's anti-tumor immune response;

[0091] Wherein: On the 7th day after intratumoral administration, the mice were killed by cervical dislocation, and the tumor tissues on both sides of the mice were taken. The tumor tissues were homogenized and centrifuged at 3500g to collect the supernatant. The IFN-γ content in each supernatant sample was detected by Mouse IFN-γ ELISA Kit and statistically analyzed;

[0092] The results showed that radiosensitizers can effectively promote T cells in the treated tumor and distal tumor to secrete more IFN-γ.

[0093] Although the present invention has been described above with reference to the embodiments, various modifications may be made thereto and parts thereof may be replaced by equivalents without departing from the scope of the present invention. In particular, as long as there is no structural conflict, the various features in the embodiments disclosed in the present invention may be used in combination with each other in any manner, and the fact that these combinations are not exhaustively described in this specification is only for the sake of omitting space and saving resources. Therefore, the present invention is not limited to the specific embodiments disclosed herein, but includes all technical solutions falling within the scope of the claims.

Claims

1. A radiotherapy sensitizer, comprising raw materials, characterized in that: The raw materials include, by weight, 10-15 parts of alkali metal hydroxide, 6-8 parts of bismuthate, 2-4 parts of sustained-release manganese composition, 4-6 parts of surfactant, 2-6 parts of hyaluronic acid, 3-5 parts of emulsifier, 1-5 parts of 5-azacytidine, 6-8 parts of mannitol, 3-6 parts of PLGA-PEI nanoparticles, 3-6 parts of amifostine, 5-8 parts of hypericin, 6-8 parts of HIF-1α-siRNA, 4-10 parts of immune agent, 1-5 parts of glutathione, and 2-4 parts of celecoxib.

2. A radiotherapy sensitizer according to claim 1, characterized in that: The ingredients in the raw materials include, by weight, 10 parts of alkali metal hydroxide, 6 parts of bismuthate, 2 parts of sustained-release manganese composition, 4 parts of surfactant, 2 parts of hyaluronic acid, 3 parts of emulsifier, 1 part of 5-azacytidine, 6 parts of mannitol, 3 parts of PLGA-PEI nano-particles, 3 parts of amifostine, 5 parts of hypericin, 6 parts of HIF-1α-siRNA, 4 parts of immune agent, 1 part of glutathione and 2 parts of celecoxib.

3. A radiotherapy sensitizer according to claim 1, characterized in that: The ingredients in the raw materials include, by weight, 12.5 parts of alkali metal hydroxide, 7 parts of bismuthate, 3 parts of sustained-release manganese composition, 5 parts of surfactant, 4 parts of hyaluronic acid, 4 parts of emulsifier, 3 parts of 5-azacytidine, 7 parts of mannitol, 4.5 parts of PLGA-PEI nanoparticles, 4.5 parts of amifostine, 6.5 parts of hypericin, 7 parts of HIF-1α-siRNA, 7 parts of immune agent, 3 parts of glutathione and 3 parts of celecoxib.

4. A radiotherapy sensitizer according to claim 1, characterized in that: The ingredients in the raw materials include, by weight, 15 parts of alkali metal hydroxide, 8 parts of bismuthate, 4 parts of sustained-release manganese composition, 6 parts of surfactant, 6 parts of hyaluronic acid, 5 parts of emulsifier, 5 parts of 5-azacytidine, 8 parts of mannitol, 6 parts of PLGA-PEI nanoparticles, 6 parts of amifostine, 8 parts of hypericin, 8 parts of HIF-1α-siRNA, 10 parts of immune agent, 5 parts of glutathione and 4 parts of celecoxib.

5. A radiotherapy sensitizer according to claim 1, characterized in that: The surfactant is polysorbate-20.

6. A radiotherapy sensitizer according to claim 1, characterized in that: The emulsifier is one or more mixtures of polyvinyl pyrrolidone, poloxamer, low molecular weight polyethylene oxide, and polyethylene glycol.

7. A radiotherapy sensitizer according to claim 1, characterized in that: The raw materials of the immune agent include, by weight: 8-12 parts of water, 4-10 parts of kiwi fruit, 2-10 parts of honey, 4-6 parts of kohlrabi, 2-6 parts of garlic, 1-5 parts of Codonopsis pilosula, 2-6 parts of Astragalus, 3-5 parts of Salvia miltiorrhiza, 4-10 parts of Cordyceps sinensis, 1-3 parts of Ganoderma lucidum, 2-6 parts of Lycium barbarum, and 1-3 parts of Angelica sinensis.

8. A radiotherapy sensitizer according to claim 7, characterized in that: The preparation process of the immunizing agent is as follows: Process 1: Use a juicer to squeeze kiwi fruit, kohlrabi, garlic, Codonopsis pilosula, Astragalus membranaceus, Salvia miltiorrhiza, Cordyceps sinensis, Ganoderma lucidum, wolfberry and angelica into juice, and then mix them; Step 2: Mix water and honey; Process 3: After the mixing is completed, the mixture in process 1 and the mixture in process 2 are mixed; Process 4: Filter the mixture in process 3 to obtain the immune agent.

9. A radiotherapy sensitizer according to claim 8, characterized in that: In the second process, the mixing temperature is 100° C.-110° C., and the mixing time is 1 min-3 min. In the third process, the mixing temperature is 110° C.-120° C., and the mixing time is 8 min-12 min.

10. A method for preparing a radiotherapy sensitizer, characterized in that: The specific steps are as follows: Step 1: respectively mixing hypericin, PLGA-PEI nanoparticles, HIF-1α-siRNA, an emulsifier, hyaluronic acid, and an alkali metal hydroxide and bismuth salt to obtain a mixture A and a mixture B; Step 2: Add the sustained-release manganese composition, surfactant, 5-azacytidine, mannitol, amifostine, immune agent, glutathione and celecoxib to the reactor in sequence for mixing, with the interval time of each component being 30s-35s to obtain mixture C, and then mix mixture A, mixture B and mixture C to obtain a radiotherapy sensitizer.